Bioequivalence of thyroid preparations: The final word?
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 1
Abstract
Authors and Affiliations
Milo Gibaldi
Keywords
Related Articles
- EP ID EP681841
- DOI 10.1208/aapsj070108
- Views 70
- Downloads 0
Pharmacokinetic model of target-mediated disposition of thrombopoietin
Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the dispo...
Design and Characterization of Novel Peptide-Coated Lipid Nanoparticles for Targeting Anti-HIV Drug to CD4 Expressing Cells
Human immunodeficiency virus (HIV) persists in lymph nodes and lymphoid tissues even during aggressive drug treatment, likely due to insufficient drug concentrations at this site. Therefore, to eliminate this residual vi...
Accelerating Drug Development Using Biomarkers: A Case Study with Sitagliptin, A Novel DPP4 Inhibitor for Type 2 Diabetes
The leveraged use of biomarkers presents an opportunity in understanding target engagement and disease impact while accelerating drug development. For effective integration in drug development, it is essential for biomar...
Targeting opioid receptor heterodimers: Strategies for screening and drug development
G-protein-coupled receptors are a major target for the development of new marketable drugs. A growing number of studies have shown that these receptors could bind to their ligands, signal, and be internalized as dimers....
A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective
Population pharmacokinetic analyses are frequently part of regulatory submissions and are mainly used to provide information on special populations (effects of age, renal impairment, etc) and drug-drug interactions. A va...